Vanguard Global Advisers
LXRX icon

Vanguard Global Advisers’s Lexicon Pharmaceuticals LXRX Stock Holding History

Vanguard Global Advisers’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$187K Sell
77,946
-15,695
-17% -$30.6K ﹤0.01% 2521
2026
Q1 		$146K Buy
+93,641
New +$136K ﹤0.01% 2573

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Global Advisers's LXRX Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Lexicon Pharmaceuticals (LXRX) stake by 17% in Q2 2026, selling an estimated $30.6K and leaving 77,946 shares worth $187K. The position accounts for ﹤0.01% of the portfolio, ranked #2521.

Vanguard Global Advisers first reported a position in LXRX in Q1 2026 and has held it in 2 quarters since. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Vanguard Global Advisers held 77,946 shares of Lexicon Pharmaceuticals worth $187K as of Q2 2026.
  • Vanguard Global Advisers sold 15,695 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $30.6K.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2521 holding.
  • Vanguard Global Advisers first reported a position in Lexicon Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.